Vir Biotechnology Inc Forecast, price target & analysts
Vir Biotechnology Inc Target price 2025 - Analyst rating & recommendation
Vir Biotechnology Inc Classifications & Recommendation:
Vir Biotechnology Inc Price Target
| Target Price | $31.13 |
| Price | $6.10 |
| Potential |
410.25%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Vir Biotechnology Inc 2026 .
The average Vir Biotechnology Inc target price is $31.13.
This is
410.25%
register free of charge
$110.00
1,703.28%
register free of charge
$14.00
129.51%
register free of charge
|
|
| A rating was issued by 9 analysts: 7 Analysts recommend Vir Biotechnology Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Vir Biotechnology Inc stock has an average upside potential 2026 of
410.25%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 74.21 | 27.41 |
| 13.89% | 63.06% | |
| EBITDA Margin | -685.70% | -1,918.26% |
| 7.89% | 179.75% | |
| Net Margin | -706.85% | -1,751.21% |
| 3.10% | 147.75% |
8 Analysts have issued a sales forecast Vir Biotechnology Inc 2025 . The average Vir Biotechnology Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Vir Biotechnology Inc EBITDA forecast 2025. The average Vir Biotechnology Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Vir Biotechnology Inc Analysts have issued a net profit forecast 2025. The average Vir Biotechnology Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.83 | -3.51 |
| 16.56% | 8.36% | |
| P/E | negative | |
| EV/Sales | negative |
6 Analysts have issued a Vir Biotechnology Inc forecast for earnings per share. The average Vir Biotechnology Inc EPS is
This results in the following potential growth metrics and future valuations:
Vir Biotechnology Inc...
Current Vir Biotechnology Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 31 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Feb 27 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 31 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Jan 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 10 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
